Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters

Kuniaki Katsui1 | Takeshi Ogata2 | Kenta Watanabe3 | Norihisa Katayama3 | Masahiro Kuroda4 | Katsuyuki Kiura5 | Takao Hiraki6 | Yoshinobu Maeda7 | Shinichi Toyooka8 | Susumu Kanazawa6

1Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
2Department of Radiology, Iwakuni Clinical Center, Yamaguchi, Japan
3Department of Radiology, Okayama University Hospital, Okayama, Japan
4Department of Radiological Technology, Graduate School of Health Sciences, Okayama University, Okayama, Japan
5Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan
6Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
7Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
8Departments of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan

Correspondence
Kuniaki Katsui, Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Email: kukatsui@cc.okayama-u.ac.jp

Funding information
This research was funded by Tsuyama Chuo Hospital. The sponsors of this research were not involved in the conduct of this study, including study design, data collection, data analysis, data interpretation, manuscript writing, or the decision to submit the manuscript for publication.

Abstract
Background: Radiation pneumonitis (RP) is a major pulmonary adverse event of chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective subsequent-line therapy after concurrent chemoradiotherapy (CCRT) found that patients with grade 2 or higher RP may have to be excluded from treatment under certain criteria. The purpose of this study was to investigate the relationship between grade ≥2 RP and the parameters of dose-volume histograms after CCRT with cisplatin/docetaxel for stage III non-small cell lung cancer and conduct a subset analysis of severe RP that can lead to the permanent discontinuation of treatment per the PACIFIC trial criteria to help determine treatment strategy.

Methods: We calculated the percentage of the lung volume received at least 5 Gy (V5) and 20 Gy (V20), the mean lung dose (MLD), and the lung volume spared from a 5 Gy dose (VS5) to the total lung volume. Factors affecting the incidence of grade ≥2 RP were identified; severe RP was defined as grade ≥3 as well as grade 2 RP that required ≥10 mg prednisolone for at least 12 weeks.

Results: This study included 45 patients. On univariate analysis, all parameters and total lung volume were found to be significant predictors of grade ≥2 RP (P = .001, .003, .03, .004, and .02, respectively). On multivariate analysis, V20 was a significant predictor.
Concurrent chemoradiotherapy (CCRT) is considered one of the standard treatments for medically inoperable stage III non-small cell lung cancer (NSCLC). The standard chemotherapy that is administered simultaneously with radiotherapy is a platinum/taxane combination. After CCRT with cisplatin/docetaxel previously showed favorable results, this regimen has since been the recommended chemotherapy in Japan. Radiation pneumonitis (RP) is a major pulmonary adverse event that can arise from chest radiotherapy; the incidences of grade ≥3 RP ranged between 1.8% and 10.0% in previous prospective studies, while grade 5 RP rates ranged between 0% and 5.6%. Several studies have clarified the relationship between RP and the parameters of the dose-volume histogram (DVH) in patients who underwent CCRT. These studies found that the lung volume percentage received at least 5 Gy (V5) and 20 Gy (V20), as well as the mean lung dose (MLD), are predictive factors for RP. Moreover Tsujino et al found that the lung volume spared from a 5 Gy dose (VS5) was also predictive of RP. Another multicenter investigation revealed that the odds ratio of symptomatic RP in patients who received CCRT with carboplatin/paclitaxel was as high as 3.33 when compared with other chemotherapy regimens. RP significantly occurred more frequently in patients undergoing CCRT with cisplatin/docetaxel than in those receiving concurrent cisplatin/vinorelbine. Although the concurrent administration of taxanes with radiotherapy is considered a risk factor for RP, no study (to our knowledge) has investigated the correlation between RP and DVH parameters in patients with lung cancer that received CCRT with a single regimen of cisplatin/docetaxel.

Recently, the breakthrough PACIFIC trial studying the administration of durvalumab after CCRT showed that the overall and progression-free survival rates were significantly higher in patients receiving durvalumab than in those receiving placebo. Since patients who develop grade ≥2 RP are no longer eligible for durvalumab, it is crucial to be able to predict the occurrence of grades ≥2 RP. Moreover durvalumab should be discontinued if either grade ≥3 RP or grade 2 RP that requires >10 mg prednisolone for over 12 weeks develops. However, the incidences of severe RP that are produced by each type of chemotherapy regimen, as well as factors that predict severe RP, remain unclear.

The aim of this study was to examine the relationship between grades ≥2 RP and parameters of DVH in patients with stage III lung cancer who received definitive CCRT with cisplatin/docetaxel and identify predictive factors for the same. Furthermore, we determined the rates of severe RP that would render patients permanently ineligible for continued durvalumab treatment under the criteria of the PACIFIC trial, and also identified DVH-related risk factors in patients with V20 values <35%.

**Methods**

**Patients**

We retrospectively evaluated patients who received definitive CCRT between January 2004 and May 2018 at the author’s hospital. The inclusion criteria were as follows: stage III NSCLC, a radiotherapy dose of 54 Gy/27 fractions to 66 Gy/33 fractions, cisplatin/docetaxel as concurrent chemotherapy regimen, and no reception of neoadjuvant chemotherapy before the start of radiotherapy. All procedures complied with the ethical standards of the 1964 Declaration of Helsinki and the subsequent amendments. Written informed consent was obtained from all patients prior to treatment. The option to opt-out was provided to all patients through notifications displayed on the hospital’s website and outpatient ward prior to the start of this study. The hospital’s review board approved this study.

**Treatment**

Staging was classified according to the 7th edition of the TNM classification of malignant tumors. Three-dimensional
conformal radiation therapy (3D-CRT) was performed for all patients. Computed tomography (CT) scans for planning were performed at 2-10 mm intervals with free-breathing without four-dimensional CT scan. The gross tumor volume is a combination of the volume of the primary tumor and clinically diagnosed metastatic lymph node. The margin of clinical target volume was 5-10 mm. When elective nodal irradiation was performed, non-metastatic subcarinal and ipsilateral hilar nodal stations were included. The attending physician decided the internal margin based on fluoroscopic images. The margin of planning target volume was 5-10 mm. The total dose was 54-66 Gy/27-33 fractions at isocenter with 10 MV photon beam generated from a linear accelerator (ONCOR, Primus or Mevatron, Canon Medical Systems, Tochigi, Japan). We calculated all plans using the XiO computer software (version 4.8.0, Electa, Stockholm, Sweden) with a non-uniformity correction algorithm as a superposition. The chemotherapy regimen used concurrently with radiotherapy was cisplatin/docetaxel, based on a prospective trial of OLCSG 0007.1

2.3 Statistical analysis and evaluation

Total lung was defined as gross tumor minus both lungs; automatic contour extraction was performed using CT-based thresholds. The RP grade was assigned using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. As DVH parameters, V5, V20, MLD, and V5S were calculated. The relationships between the incidences of grades ≥ 2 RP and parameters of DVH were analyzed using the log-rank test for univariate analysis and the Cox proportional hazard model for multivariate analysis. Cutoff values for continuous variables were decided from individual receiver operating characteristic (ROC) curves before performing the log-rank test. The cutoff values at the maximal point of the Youden Index were adopted. The associations between total lung volume and DVH parameters were tested using the Pearson product-moment correlation coefficient. Severe RP that would cause permanent treatment discontinuation according to the PACIFIC trial criteria was defined as either grade ≥ 3 or grade 2 that required the maintenance of >10 mg prednisolone for more than 12 weeks.14 Because the V20 of the DVH parameters in the PACIFIC trial was below 35%, the rate of severe RP was calculated for patients in our study with V20 values below 35%. The cumulative incidence rate of RP was calculated using the Kaplan-Meier method; the RP rate was also stratified according to significant factors on univariate analysis. Two-tailed P-values of <.05 were considered to be significant predictors. All statistical tests were performed using The R software, version 3.2.0 (R Foundation for Statistical Computing).

3 RESULTS

Table 1 shows the characteristics of the 45 patients who met the eligibility criteria. The total dose of radiation therapy was 60 Gy in 44 patients and 54 Gy in 1 patient. The median V5, V20, MLD, V5S, and total lung volume were 41.45%

| TABLE 1 Patient characteristics |
|---------------------------------|
| Age (years) Median (range) 63 (36-84) – |
| Sex Male 41 91 |
| Female 4 9 |
| ECOG-PS 0 18 40 |
| 1 27 60 |
| Smoking history Never 1 2 |
| Former 19 42 |
| Current 25 56 |
| Lobea Upper 36 80 |
| Lower 8 18 |
| Lateralitya Right 24 53 |
| Left 20 44 |
| Histology Adenocarcinoma 14 31 |
| Squamous cell carcinoma 27 60 |
| Non-small cell carcinoma 4 9 |
| C-stage IIIA 7 16 |
| IIIB 38 84 |
| FEV1 (l)a Median (range) 2.35 (0.48-4.11) – |
| FVC (l)a Median (range) 3.32 (1.51-6.35) |
| %VC (%) Median (range) 96.9 (62.7-159.8) |
| Total lung volume (cm3) Median (range) 3176.94 (1979-4833) – |
| Tumor size (mm) Median (range) 55.0 (10.0-111.0) – |
| GTV volume (cm3) Median (range) 167.61 (128.38-745.31) – |
| V5 (%) Median (range) 41.45 (17.86-72.59) – |
| V20 (%) Median (range) 27.48 (10.10-48.59) – |
| MLD (Gy) Median (range) 14.89 (6.07-22.62) – |
| V5S (cm3) Median (range) 1980.2 (612.3-3376.5) – |

Abbreviations: %VC, % vital capacity; ECOG-PS, Eastern Cooperative Oncology Group performance status; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GTV, gross tumor volume; MLD, mean lung dose of the lung; V20, percentage of the lung volume received at least 20 Gy; V5, percentage of the lung volume received at least 5 Gy; V5S, volume of the lung spared from 5 Gy.

aThese factors have missing values.
(range: 17.86%-72.59%), 27.48% (range: 10.1%-48.59%), 14.89 Gy (range: 6.07-22.62 Gy), 1980.24 cm$^3$ (range: 612.30-3376.51 cm$^3$), and 3176.94 cm$^3$ (range: 1987.64-4832.98 cm$^3$), respectively. Grades 0, 1, 2, 3, 4, and 5 RP developed in 1 (2.2%), 23 (51.1%), 16 (35.6%), 3 (6.7%), 0 (0.0%), and 2 (4.4%) of the patients, respectively. The median follow-up period was 20.0 months (range 2.4-151.8 months).

Figure 1 shows individual ROC curves. In ROC analysis, we found that V5, V20, MLD, VS5, and TLV cutoff values of 41%, 28%, 15 Gy, 1950 cm$^3$, and 3680 cm$^3$ provided the best combination of sensitivity and specificity. Sensitivity/specificity were 0.762/0.75, 0.714/0.792, 0.81/0.667, 0.714/0.75, and 0.952/0.417, respectively. Results of univariate and multivariate analyses of factors affecting ≥2 RP are shown in Table 2. On univariate analysis, the V5, V20, MLD, VS5, and total lung volume were significant predictors of grade ≥ 2 RP ($P = .001, .003, .03, .004, and .02$, respectively). The absolute Pearson correlation coefficients between V5/V20, V5/MLD, V5/VS5, V20/MLD, V20/VS5, MLD/VS5, and VS5/total lung volume were 0.940, 0.885, 0.732, 0.955, 0.711, 0.706, and 0.753, respectively. In contrast, the correlation coefficients between V5/
From among the V5, V20, MLD, and VS5, we selected V20 for multivariate analysis based on Tsujino et al’s study.12 On multivariate analysis, V20 was a significant predictor (P = .007), whereas total lung volume was not (P = .055) on multivariate analysis.

The median duration between the end of definitive CCRT and the development of grade ≥ 2 RP was 11.29 weeks (range: 1.57-32.57 weeks). The Kaplan-Meier curve for the cumulative incidence of grade ≥ 2 RP is shown in Figure 2; incidence rates were 42.8% (95% confidence interval [CI]: 26.2-55.6%) at 6 months and 47.6% (95% CI: 30.5%-60.5%) at 12 months. The Kaplan-Meier curves for the cumulative incidence of grade ≥ 2 RP were stratified according to the five factors that were significant predictors on univariate analysis are shown in Figure 3. The incidence rates of grade ≥ 2 RP after 6 months were as follows: 18.9% and 69.6% in patients with V5 values of < 41% and ≥ 41%, respectively; 17.8% and 68.2% in patients with V20 values of < 28% and ≥ 28%, respectively; 22.2% and 63.6% in patients with MLDs of < 15 Gy and ≥ 15 Gy, respectively; 66.7% and 21.1% in patients with VS5 values of < 1950 cm3 and ≥ 1950 cm3, respectively; and 66.7% and 21.1% in patients with total lung volumes of < 3680 and ≥ 3680 cm3, respectively.

Thirty-seven of the 45 patients had a V20 of 35% or less. Grades 0, 1, 2, 3, 4, and 5 RP developed in 1 (1.4%), 21 (56.8%), 12 (32.4%), 2 (5.4%), 0 (0.0%), and one (1.4%) of the patients, respectively. Severe RP that would require permanent treatment discontinuation according to the PACIFIC trial criteria developed in 6 (16.2%) of the 37 patients. The V20 cutoff value calculated using the ROC curves was 28.5%; on univariate analysis, V20 was the only significant predictor of severe RP in this subgroup (P = .01).

### TABLE 2 (Continued)

| Factor                | N    | Univariate P-value | Multivariate P-value |
|-----------------------|------|--------------------|----------------------|
| MLD (Gy)              |      |                    |                      |
| <15                   | 7/23 | .03                | NE                   |
| ≥15                   | 14/22|                    |                      |
| VS5 (cm³)             |      |                    |                      |
| <1950                 | 15/21| .004               | NE                   |
| ≥1950                 | 6/24 |                    |                      |

Abbreviations: %VC, % vital capacity; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GTV, gross tumor volume; MLD, mean lung dose of the lung; NE, not entered; V20, percentage of the lung volume received at least 20 Gy; V5, percentage of the lung volume received at least 5 Gy; VS5, volume of the lung spared from 5 Gy.

*These variables have missing values.
Radiation pneumonitis is a noteworthy adverse event in patients who have undergone definitive radiotherapy for NSCLC; V20 and MLD are major predictors among the various DVH parameters. Graham et al found that V20 was a predictive factor of grades ≥2 RP on univariate and multivariate analyses; the incidences of grade ≥2 RP at 24 months were 0%, 8%, 13%, and 36% in patients with V20 values of <22%, 22%-31%, 32%-40%, and >40%, respectively. Forty-two percent of patients received neoadjuvant or concurrent chemotherapy, V20 was related to grade ≥2 RP on univariate analysis. As the incidence of RP appeared to be elevated with the use of steroids for grading pneumonitis. Dang et al investigated RP in 369 patients with lung cancer using the CTCAE version 4 and found that V20 was a significant predictor associated with RP on univariate analysis. Consistent with such previous studies, the V20 was found to be a significant predictive factor of RP on univariate and multivariate analyses in our study. The cumulative incidence rates of grade ≥2 RP after 6 months were 17.8% and 68.2% in patients with V20 values <28% and ≥28%, respectively. Although the diagnostic criteria and cut-off values for RP in our study were different, the rates of grade ≥2 RP as stratified by V20 was close to that of Tsujino et al.

Mean lung dose is a predictive factor of RP in patients who received definitive CCRT. In Barriger et al's study, the incidence rates of grade ≥2 RP were 2.2% and 19% in patients whose MLDs are <18 and >18 Gy, respectively. The MLD threshold for maintaining the risk of symptomatic RP ≤20% was 20-23 Gy. In our study, MLD was a significant predictive factor of grade ≥2 RP on univariate analysis (P = .03). Palma et al also presented MLD to be a predictive factor of RP in patients ≤65 years of age who received CCRT using carboplatin/paclitaxel chemotherapy, according to recursive partitioning analysis; their threshold was 10 Gy. In the study by Dang et al, MLD was found to be a predictor for RP on univariate and multivariate analyses; MLD of patients with grade 1 RP was 14.15 ± 3.26 Gy, that for patients with grade 2 RP was 17.71 ± 3.28 Gy, and that for patients with grades 3-5 RP was 21.4 ± 3.48 Gy. MLDs for all patients who developed RP of grades ≥2 were, therefore, between 17 Gy and 21 Gy. In our study, the MLD threshold for developing RP, as obtained from the ROC curve, was 15 Gy. Although an accurate comparison was not possible because MLD associated with grade ≥2 RP was unknown, and patients other than those who received concurrent chemotherapy were also included in their study, our value was close to theirs.

In a previous analysis of 22 patients who received intensity-modulated radiotherapy (IMRT), V5 was found to be a prognostic factor for grade ≥3 RP. The incidence of grade ≥3 RP RP after 12 months was 2% in patients with V5 values ≤70% but was 21% in those with values >70% (P = .017). Similarly, V5 was a significant predictor of RP on univariate analysis in our study. In Yom et al's study, the median V5 was significantly higher in the IMRT group (63%, range: 5%-98%) than in the 3D-CRT group (57%, range: 12%-98%). Moreover the median V20 in the IMRT group (35%, range: 3%-48%) was lower than that in the 3D-CRT group (38%, range: 8%-78%); the MLDs were not significantly different. The incidence rates of grade ≥3 RP after 12 months were 8% for patients who received IMRT and 32% for those receiving 3D-CRT. It was posited that the decrease in V20 contributed to a decrease in the incidence of RP. In a randomized trial by Liao et al comparing the outcomes of passive scattering proton therapy (PSPT) to those of IMRT, PSPT resulted in a lower lung V5-10 but higher lung V20-80 than did IMRT. The rates of grade ≥3 RP did not differ between the 2 groups. Like in Tsujino et al's study, V5 correlated with other DVH parameters in our study; hence, it is necessary to plan treatments while considering all the parameters. Additional research is required to ascertain the effects of low-dose radiation on the lung and determine the optimal balance.
between the various DVH parameters that minimizes the risk of PR caused by CCRT with cisplatin/docetaxel.

Tsujino et al investigated the relationship between RP and VS5 and found that a VS5 < 1500 cm³ was a significant predictive factor of grade ≥ 3 RP. The incidences of grade ≥ 3 PR were 7.3% and 50% for patients in whom the VS5 values were ≥1500 and <1500 cm³, respectively. Chen et al also showed VS5 to be a predictive factor of grade ≥ 2 RP in patients treated with IMRT. The incidence rate of grade ≥ 2 RP was significantly lower when VS5 of the ipsilateral lung was ≥564.9 cm³ than it was with VS5 values <564.9 cm³. VS5 of the ipsilateral lung was a predictor of grade ≥ 2 RP. Chen et al’s study demonstrated the importance of the VS5, even though they included small cell lung cancer patients; moreover, they used the toxicity criteria of the RTOG. In our study, VS5 was also found to be a predictor of grade ≥ 2 PR, considering that VS5 and other parameters may contribute to improving the clinical courses of patients with NSCLC who undergo CCRT with cisplatin/docetaxel.

A multicenter study by Palma et al reported that undergoing chemotherapy was a predictive factor for symptomatic RP; its odds ratio with carboplatin/paclitaxel relative to cisplatin/etoposide was 3.33 (P < .001). Onishi et al showed that the incidence of grade ≥ 3 RP was as high as 47% in patients who received weekly docetaxel and 2-dimensional radiotherapy. In Dang et al’s study, the incidence rates of grade ≥ 2 were 39.7%, 31%, and 33.6% in patients who received concomitant cisplatin/docetaxel, concomitant cisplatin/vinorelbine, and sequential chemotherapy after radiotherapy; the corresponding incidence rates of grade ≥ 3 RP were 18.4%, 9.5%, and 11.2%, respectively. The incidence of grade ≥ 3 RP was higher in the concomitant cisplatin/docetaxel group.
than in the concomitant cisplatin/vinorelbin group. While a comparison of RP incidences between Dang et al’s study and our study should be performed with caution due to the lack of reporting of DVH parameters in their cisplatin/docetaxel group, the incidence rate of grade ≥ 2 RP in our study was 47.6% at 12 months, which was slightly higher than that in their study. IMRT was associated with a lower incidence rate of grade ≥ 3 RP; 22% of the patients in their study received IMRT, which may explain this result. To our knowledge, ours is the first study to show the incidence of grade ≥ 2 RP and its associated DVH parameters in patients undergoing definitive CCRT with cisplatin/docetaxel.

Programmed death 1 (PD-1) and PD-1 ligand 1 (PD-L1) are important molecules in immune regulation. In comparison with docetaxel, Nivolumab, a PD-1 inhibitor, improved OS rates in patients previously treated with squamous-cell lung cancer. Pneumonitis is a serious adverse event caused by the use of PD-1 inhibitors, leading to the discontinuation of cancer therapy, with resultant mortality. Durvalumab blocks the interaction between PD-L1 and PD-1, but does not bind to PD-1 ligand 2 (PD-L2). Khunger et al showed that the incidence of pneumonitis were 3.6% and 1.3% in the PD-1 and PD-L1 inhibitor groups, respectively. The incidence of pneumonitis in patients who received PD-1 inhibitors was significantly higher than that of PD-L1 inhibitors.

One reason for the lower rate of pneumonitis in PD-L1 inhibitors is the presence of PD-L2. PD-L2 might play an important role in accommodating immune tolerance in the lungs; it interacts with PD-1 and is affected by PD-1 inhibitors. In a study involving murine models, Xiao et al suggested that PD-1 blockade may shift the balance of PD-L2 interaction with binding partners, and increase the capacity of PD-L2 binding to repulsive guidance molecule b, which is able to lead to pneumonitis. Further experimental investigations about pneumonitis induced by combination therapy of PD-L1 inhibitor and radiotherapy are warranted.

Durvalumab cannot be administered if grade ≥ 2 RP occurs. As such, the management of grade ≥ 2 RP became more urgent after the publication of the PACIFIC trial that showed the benefits of durvalumab treatment after chemoradiotherapy. In the study by Hosoya et al, 19 of 82 patients (23%) became ineligible for durvalumab treatment (as specified by the PACIFIC trial criteria) after receiving CCRT; of these 19 patients, 6 developed grade ≥ 2 RP within 42 days after CCRT. Their study further revealed that old age, male sex, and radiotherapy with a V20 ≥ 35% were related to durvalumab ineligibility after CCRT. In the PACIFIC trial, the hazard ratio for death was 0.42 for patients who commenced treatment with durvalumab < 14 days after completing CCRT, and was 0.81 for those who commenced treatment ≥ 14 days after CCRT. These data showed that the early introduction of durvalumab was beneficial and that physicians do not have to wait 42 days after CCRT before administering this agent. Pneumonitis had the highest incidence rate of all adverse events that led to the criteria for the discontinuation (4.8% of the patients in the durvalumab group and 2.6% of those in the placebo group) and RP (1.3% and 1.3%, respectively). Additionally, a criterion for the discontinuation of durvalumab in the PACIFIC trial was the occurrence of severe grade ≥ 2 RP that required > 10 mg prednisolone for more than 12 weeks; moreover, the V20 was required to be 35% or lower to avoid the occurrence of RP. In our study, severe RP that met the PACIFIC trial’s abovementioned criterion for permanent discontinuation of durvalumab occurred in 6 of 37 patients (16.2%) who had V20 values of ≤35%. Only the V20 was a significant predictive factor of RP on univariate analysis despite the small sample size. In the PACIFIC trial, RP of all grades occurred in 20.2% of patients who received the durvalumab and 15.8% of those who received placebo; hence, durvalumab appeared to increase the risk of pneumonitis slightly. According to our data, the incidence of severe RP is likely to be 16.2% or higher if durvalumab is started immediately after the end of CCRT using cisplatin/docetaxel. Because details regarding radiotherapy in the PACIFIC trial have not yet been published, additional research is required to determine the effects of durvalumab on the lung after CCRT, as well as the associated DVH parameters, in patients who discontinue treatment.

Grade 5 RP developed in two patients in our study (4.4%). In previous prospective trials, the V20 value was not among the eligibility criteria. Grade 5 RP occurred in 1.9% of the patients undergoing CCRT with carboplatin/paclitaxel in the West Japan Thoracic Oncology Group 0105 trial and 2.0% of those undergoing the same treatment in the OLCSG 0007 trial. In recent prospective trials, the V20 has been limited to 35% or less. Two of the 283 patients (0.7%) in the CCRT with cisplatin/pemetrexed group of the PROCLAIM study died of possible RP, while no grade 5 RP occurred among patients receiving CCRT plus cisplatin/etoposide. Although the incidence of grade 5 RP appeared to have decreased slightly after restricting the V20 values, grade 5 RP still occurred in 5.3% and 1.9% of patients administered cisplatin/S-1 and cisplatin/vinorelbine in the West Japan Oncology Group 5008L study of Japanese patients. Hence, Japanese patients receiving CCRT should be monitored for grade 5 RP, as risk factors other than the DVH parameters may exist (this requires additional investigation).

To the best of our knowledge, ours is the first study to determine the predictive factors for grade ≥ 2 or severe RP that would require permanent treatment discontinuation under the PACIFIC trial criteria in patients administered CCRT with cisplatin/docetaxel. There were several limitations in our study. First, this was a retrospective analysis with small sample size. Therefore, more studies with more lung cancer patients receiving CCRT with cisplatin/
docetaxel are needed to confirm the prognostic value of V20. Second, assessments of important factors, such as single nucleotide polymorphisms and background lung disease, were not performed. For example, Xu et al24 reported that genetic variants of surfactant protein D were associated with the development of RP. Third, we only evaluated RP but not other types of adverse events that could also lead to permanent treatment discontinuation according to the PACIFIC trial criteria.

5 CONCLUSION

V20 is a significant predictor of grade $\geq 2$ and severe RP. Severe RP that would lead to permanent discontinuation of treatment according to the PACIFIC trial criteria developed in 16.2% of the patients who received definitive CCRT with cisplatin/docetaxel. Detailed future investigations of the relationship RP and parameters of DVH in patients who receive durvalumab as part of a concurrent chemotherapy regimen are warranted.

ACKNOWLEDGMENTS

We sincerely appreciate all the patients who underwent treatment as part of this study.

CONFLICT OF INTERESTS

KK1 received honoraria from AstraZeneca, outside the submitted work. KK1 belongs to the donation course funded by Tsuyama Chuo Hospital; KK2 received honoraria from AstraZeneca outside the submitted work.

AUTHORS' CONTRIBUTIONS

KK1 participated in the design of the study, performed treatment, collected the data, and drafted the manuscript; TO participated in the design of the study, performed treatment, and performed statistical analysis; KW participated in the design of the study, collected the data, and performed treatment; NK, ST, and KK2 participated in the design of the study and performed treatment; MK, TH, YM, and SK participated in the design of the study. All authors read and approved the final manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The institutions’s review board approved this study (approval number: 1809-018). Written informed consent was obtained prior to treatment. The choice to opt-out was provided through notifications displayed on the hospital’s website and outpatient ward before the start of this study.

DATA AVAILABILITY STATEMENT

The institution’s review board prohibits data sharing.

REFERENCES

1. Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010;28(20):3299-3306.
2. Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28(23):3739-3745.
3. Senan S, Brade A, Wang LH, et al. PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953-962.
4. Sasaki T, Seto T, Yamanaka T, et al. A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. Br J Cancer. 2018;119:675-682.
5. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45(2):323-329.
6. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2003;55(1):110-115.
7. Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, McGarry RC. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys. 2010;78(5):1381-1386.
8. Dang J, Li G, Zang S, Zhang S, Yao L. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. Radiat Oncol. 2014;9:172.
9. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76(Suppl):S70-S76.
10. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(1):94-102.
11. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85(2):444-450.
12. Tsujino K, Hashimoto T, Shimada T, et al. Combined analysis of V20, V5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(7):983-990.
13. Chen J, Hong J, Zou X, et al. Association between absolute volumes of lung spared from low-dose irradiation and radiation-induced pneumonitis in patients with locally advanced non-small-cell lung cancer: a pooled analysis of two randomized phase III trials. J Thorac Oncol. 2018;13(4):526-532.

ORCID

Kuniaki Katsui https://orcid.org/0000-0002-1842-2485
lung injury after intensity-modulated radiotherapy in lung cancer: a retrospective analysis. J Radn Res. 2015;56(6):883-888.

14. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. New Engl J Med. 2017;377:1919-1929.

15. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. New Engl J Med. 2018;379(24):2342-2350.

16. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(18):1813-1822.

17. Onishi H, Kuriyama K, Yamaguchi M, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer. 2003;40(1):79-84.

18. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56-62.

19. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New Engl J Med. 2015;373(2):123-135.

20. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052-1062.

21. Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest. 2017;152(2):271-281.

22. Xiao Y, Sanhong YU, Zhu B, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014;211(5):943-959.

23. Hosoya K, Fujimoto D, Kawachi H, et al. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2019;84(2):275-280.

24. Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010;77(2):357-366.

How to cite this article: Katsui K, Ogata T, Watanabe K, et al. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. Cancer Med. 2020;00:1–10. https://doi.org/10.1002/cam4.3093